,7-二甲氧基-1,2,3,4-四羟基异喹啉-1-硫酮 | 24456-59-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: ,7-二甲氧基-1,2,3,4-四羟基异喹啉-1-硫酮
• 中文别名: 6,7-二甲氧基-1,2,3,4-四氢异喹啉-1-硫酮；二甲氧基四羟基异喹啉硫酮；7-二甲氧基-1,2,3,4-四羟基异喹啉-1-硫酮
• 英文名称: 6,7-dimethoxy-3,4-dihydroisoquinoline-1(2H)-thione
• 英文别名: 6,7-dimethoxy-3,4-dihydro-2H-isoquinoline-1-thione
• CAS: 24456-59-5
• 化学式: C₁₁H₁₃NO₂S
• mdl: MFCD00143491
• 分子量: 223.296
• InChiKey: CTIOPTPZTOYIHL-UHFFFAOYSA-N

物化性质

• 熔点：
  223-226 °C
• 沸点：
  354.3±52.0 °C(Predicted)
• 密度：
  1.2144 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 海关编码：
  2933499090

SDS

Name:	6 7-Dimethoxy-1 2 3 4-Tetrahydroisoquinoline-1-Thione 99% Material Safety Data Sheet
Synonym:	None known
CAS:	24456-59-5

Section 1 - Chemical Product MSDS Name:6 7-Dimethoxy-1 2 3 4-Tetrahydroisoquinoline-1-Thione 99% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
24456-59-5	6,7-Dimethoxy-1,2,3,4-Tetrahydroisoqui	99	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 24456-59-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 223.00 - 226.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble in dmso,hot chloroform
Specific Gravity/Density:
Molecular Formula: C11H13NO2S
Molecular Weight: 223.30

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide, hydrogen sulfide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 24456-59-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinoline-1-Thione - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 24456-59-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 24456-59-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 24456-59-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  ,7-二甲氧基-1,2,3,4-四羟基异喹啉-1-硫酮 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 6-methylthio-7-phenoxy-2',3'-dimethoxybenzooctem
  参考文献：
  名称：

  某些多环顺式-β-内酰胺的立体定向合成

  摘要：

  与吡啶中的P 2 S 5反应的酰胺1得到硫代酰胺2，其在用碘代甲烷处理后得到相应的1-甲硫基-3，4-二氢异喹啉3。在三乙胺存在下，将这些亚胺与苯氧乙酰氯进行退火，得到6-甲硫基-7-苯氧基-2'，3'-二甲氧基苯并[ a ]辛基4a和6-甲硫基-7-苯氧基-2,3-亚甲基二氧苯并[a]八进制4b。用阮内镍将这些β-甲硫基-β-内酰胺脱硫，得到新颖的多环顺式-β-内酰胺5a和5b。

  DOI：

  10.1016/0040-4020(80)80195-5
• 作为产物：
  描述：

  2-(3,4-二甲氧基苯基)乙基异硫代氰酸酯 在 polyphosphoric acid 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以17 g的产率得到,7-二甲氧基-1,2,3,4-四羟基异喹啉-1-硫酮
  参考文献：
  名称：

  去甲基化的Lactonization为Lamellarins的高产率合成提供了捷径。

  摘要：

  薄层蛋白G（6）和D（7）的三甲醚的模块化克级合成方法是从易于获得的前体中获得的，迄今报道的最高总收率（6步，82步，7步，7步，86％） ）。开发了一种在芳基甲基醚和相邻的羧酸之间的新型脱甲基内酯化反应，以产生靶标的色酮单元，从而避免了额外的保护和脱保护步骤。中心吡咯核是在溴乙酸乙酯和拥有层状蛋白骨架其余成分的烯胺酮之间的后期[4 +1]缩合反应中构建的。过甲醚6和7的彻底脱甲基分别得到多酚天然薄片蛋白A4（3）和H（5）。

  DOI：

  10.1021/acs.joc.9b02983

文献信息

• Synthesis and spectroscopic studies of some hydrogenated thiazolo[2,3- a ]isoquinolines
  作者：Maria D Rozwadowska、Agnieszka Sulima

  DOI：10.1016/s0040-4020(01)00224-1

  日期：2001.4

  4-dihydroisoquinoline derivatives under the action of α-mercapto alkanoic acids or ethylene sulfide, respectively. In the synthesis of compounds 2 and 5 isothiocarbostril (13) and N-thioacetyl-β-phenylethylamine derivatives (14), respectively, were also used as substrates and treated with bromoacetic acid derivatives. Spectral characteristics (IR, 1H, 13C NMR and MS) of compounds 1–12 are presented.

  二氢-5- ħ -噻唑并[2,3-一个]异喹啉酮（1 - 6）和四氢-5- ħ -噻唑并[2,3一]异喹啉（7 - 12）已经从下3,4-二氢异喹啉衍生物制备α-巯基链烷酸或亚乙基硫的作用。在化合物2和5的合成中，异硫脲化合物（13）和N-硫代乙酰基-β-苯乙胺衍生物（14）也分别用作底物，并用溴乙酸衍生物处理。光谱特性（IR，1 H，给出了化合物1 – 12的13 C NMR和MS）。
• 2(1H)-quinolinone compounds and pharmaceutical composition comprising
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04988698A1

  公开（公告）日：1991-01-29

  This invention relates to new 2(1H)-quinolinone compounds having the formula: ##STR1## wherein R.sup.1 is a imidazopyridyl, thiazolyl, indolyl, dihydroindolyl, imidazolyl, benzimidazolyl, quinolyl, isoquinolyl, quinazolinyl, dihydroisoquinolyl, tetrahydroimidazopyridyl or tetrahydroquinolyl, each of which may be substituted with substituents(s) selected from the group consisting of lower alkyl, halogen, lower alkoxy, lower alkylthio, ar(lower)alkoxy, cyano, nitro, amino, lower alkylamino, acylamino, hydroxy and oxo, R.sup.2 is hydrogen, lower alkyl or halogen, A is a single bond or a group of the formula selected from the group consisting of: ##STR2## and --X--CO--, in which X is a single bond or lower alkylene and X.sup.1 is lower alkylene, and a heavy solid line means a single or a double bond, and its pharmaceutically acceptable salt. Said compounds are used in the therapeutic treatment of heart diseases and hypertension in human beings and other animals.

  本发明涉及具有以下结构式的新2(1H)-喹啉酮化合物： 其中R.sup.1是咪唑吡啉基、噻唑基、吲哚基、二氢吲哚基、咪唑基、苯并咪唑基、喹啉基、异喹啉基、喹唑啉基、二氢异喹啉基、四氢咪唑吡啉基或四氢喹啉基，每个基可能被取代为从以下基团中选择的取代基，所述基团包括低烷基、卤素、低烷氧基、低烷硫基、芳基(低)氧基、氰基、硝基、氨基、低烷基氨基、酰氨基、羟基和羰基，R.sup.2是氢、低烷基或卤素，A是单键或从以下结构式组中选择的一个： --X--CO--， 其中X是单键或低烷基亚烷基，X.sup.1是低烷基亚烷基，粗实线表示单键或双键，以及其药用可接受的盐。该化合物用于治疗人类和其他动物的心脏疾病和高血压。
• Practical Decagram-Scale Synthesis of a Lamellarin Analogue and Deprotection of Lamellarin Isopropyl Ethers
  作者：Robin Klintworth、Charles B. de Koning、Joseph P. Michael

  DOI：10.1002/ejoc.202000499

  日期：2020.7.7

  Lamellarin ε and dehydrolamellarin J were synthesized via enaminones by operationally simple routes that included a mild new method for the nearly quantitative deprotection of isopropyl‐protected phenols with methanesulfonic acid. The synthesis of dehydrolamellarin J could be scaled up to provide over 25 g of product without the need for chromatography.

  Lamellarinε和Dehydrolamellarin J是通过操作简单的途径通过烯胺酮合成的，其中包括使用温和的新方法对异丙基保护的苯酚进行甲磺酸近乎定量的脱保护。可以扩大脱氢薄片蛋白J的合成规模，从而无需色谱即可提供超过25 g的产物。
• Total synthesis of racemic 1-aryl-tetrahydroisoquinoline alkaloids
  作者：Péter Ábrányi-Balogh、Tamás Földesi、Mátyás Milen

  DOI：10.1007/s00706-015-1564-y

  日期：2015.11

  AbstractA new synthetic route was developed for the preparation of natural products cryptostyline I, II, III and 1-phenyl-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline. The Liebeskind–Srogl palladium-catalyzed carbon–carbon cross-coupling protocol was used in the key step of the total synthesis. Graphical abstract

  摘要开发了一条新的合成路线，用于制备天然产物隐甲菊碱I，II，III和1-苯基-6,7-二甲氧基-2-甲基-1,2,3,4-四氢异喹啉。Liebeskind-Srogl钯催化的碳-碳交叉偶联方案用于总合成的关键步骤。 图形概要
• 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0370381A2

  公开（公告）日：1990-05-30

  1. A compound of the formula : wherein R¹ is imidazopyridyl, thiazolyl, indolyl, dihydroindolyl, imidazolyl, benzimidazolyl, quinolyl, isoquinolyl, quinazolinyl, dihydroisoquinolyl, tetrahydroimidazopyridyl or tetrahydroquinolyl, each of which may be substituted with substituent(s) selected from the group consisting of lower alkyl, halogen, lower alkoxy, lower alkylthio, ar(lower)alkoxy, cyano, nitro, amino, lower alkylamino, acylamino, hydroxy and oxo, R² is hydrogen, lower alkyl or halogen, A is a single bond or a group of the formula selected from the group consisting of : -CO-X, --X- and -X-CO-, in which X is a single bond or lower alkylene and X¹ is lower alkylene, and a heavy solid line means a single or a double bond, and its pharmaceutically acceptable salt, processes for their preparation and pharmaceutical compositions comprising them as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

  1.式中的化合物 其中 R¹ 是咪唑吡啶基、噻唑基、吲哚基、二氢吲哚基、咪唑基、苯并咪唑基、喹啉基、异喹啉基、喹唑啉基、二氢异喹啉基、四氢咪唑吡啶基或四氢喹啉基、R²为氢、低级烷基、卤素、低级烷氧基、低级烷硫基、芳基（低级）烷氧基、氰基、硝基、氨基、低级烷基氨基、酰氨基、羟基和氧代、 R² 是氢、低级烷基或卤素、 A 是单键或从以下组中选出的式中基团：： -CO-X、--X- 和 -X-CO-，其中 X 是单键或低级亚烷基，X¹ 是低级亚烷基，以及 重实线表示单键或双键、 及其药学上可接受的盐、其制备工艺和包含它们作为活性成分的药物组合物，与药学上可接受的、基本上无毒的载体或赋形剂一起使用。